<div id="readability-page-1"><div><ul> <li>Earlier this month, Nuvation Bio announced that the FDA accepted a supplemental New Drug Application for IBTROZI with additional long-term efficacy and safety data in advanced ROS1-positive non-small cell lung cancer, while also completing a U.S. manufacturing technology transfer to Thermo Fisher Scientific.</li> <li>Together, the strengthened clinical dataset and secured domestic supply chain deepen IBTROZI’s profile as a CNS-active ROS1 therapy with growing global reach and operational resilience.</li> <li>We’ll now examine how the FDA’s acceptance of the supplemental IBTROZI filing may influence Nuvation Bio’s longer-term investment narrative.</li> </ul><p>Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</p><h2>Nuvation Bio Investment Narrative Recap</h2><p>To own Nuvation Bio, you have to believe IBTROZI can anchor a durable ROS1 lung cancer franchise while safusidenib eventually becomes a second revenue pillar. The key near term catalyst is the FDA’s January 2027 sNDA decision for IBTROZI, which this updated long term dataset directly supports. The biggest risk remains reliance on IBTROZI while safusidenib’s pivotal data sit years away, leaving the business exposed if ROS1 competition or access challenges intensify.</p> <p>The most relevant update here is the FDA’s acceptance of the IBTROZI sNDA with an extra 10 months of TRUST-I and TRUST-II follow up. Those data, including a reported median duration of response of 49.7 months in TKI naive patients and a consistent safety profile, go straight to the heart of IBTROZI’s label and prescribing confidence, and therefore into how investors think about the drug’s future contribution.</p> <p>Yet against this progress, investors should also weigh the risk that faster emerging ROS1 competitors could still pressure IBTROZI’s position over time...</p> <p>Read the full narrative on Nuvation Bio (it's free!)</p><p>Nuvation Bio's narrative projects $427.2 million revenue and $5.2 million earnings by 2028. This requires 151.8% yearly revenue growth and a $222.7 million earnings increase from $-217.5 million.</p><p>Uncover how Nuvation Bio's forecasts yield a $10.25 fair value, a 142% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1d2ddebb-038e-4cd4-82b7-a76373f619a3/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1d2ddebb-038e-4cd4-82b7-a76373f619a3/chart/quote-price"/><figcaption>NUVB 1-Year Stock Price Chart</figcaption></figure> <p>Some of the most optimistic analysts were already assuming IBTROZI would help drive revenue to about US$522,300,000 and earnings to roughly US$38,000,000 by 2028, which is far above the consensus view. In light of the new IBTROZI data and manufacturing news, you might find that this more aggressive story around IBTROZI’s long term role and competitive threats looks either more achievable or more stretched, so it is worth comparing these different viewpoints before deciding where you stand.</p><p>Explore 8 other fair value estimates on Nuvation Bio - why the stock might be worth less than half the current price!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Nuvation Bio research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.</li><li>Our free Nuvation Bio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nuvation Bio's overall financial health at a glance.</li></ul><h2>Curious About Other Options?</h2><p>Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:</p><ul><li>Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.</li><li>The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.</li><li>AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if Nuvation Bio might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

NUVB

<p>Nuvation Bio's recent FDA acceptance of a supplemental New Drug Application for IBTROZI enhances its long-term investment narrative in oncology. The updated efficacy and safety data for advanced ROS1-positive lung cancer, along with a manufacturing transfer to Thermo Fisher, bolster IBTROZI's market position. Analysts project significant revenue growth, with a fair value estimate of $10.25, indicating a potential 142% upside. However, competition risks remain, necessitating careful evaluation of investment strategies.</p>

Simplywall

Nuvation Bio

Thermo Fisher Scentific

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

iShares Global Healthcare

ALPS Medical Breakthrough

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

NVIDIA

Microsoft

NUVATION BIO INC C/WTS 10/02/2026 (TO PUR COM)

NVIDIA Corporation

How Does Nuvation Bio’s (NUVB) IBTROZI Update Reframe Its Long-Term Oncology Investment Narrative?